Biora Therapeutics, Inc.
BIORDelisted Jun 4, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580063
Biora Therapeutics, Inc. was delisted on Jun 4, 2025; its insiders filed their last Form 4 on Dec 16, 2024; 21 institutions reported holding it in 13F filings for Q3 2024, worth $6.13M in total; no superinvestor held it.
Q4 2024 vs. Q3 2024
How the institutions holding Biora Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 21 | 1 | 0 | −20 |
| Shares | 12.2M | 10.9M | 0 | −1.29M (−100.0%) |
| Value | $6.13M | $5.48M | $0 | −$644.7K (−100.0%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Biora Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
None.
Sold out (20)
Institutions that held Biora Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Vanguard Group Inc | 697,330 | $350.1K |
| Geode Capital Management, LLC | 156,298 | $78.4K |
| Morgan Stanley | 145,028 | $72.7K |
| Northern Trust Corp | 68,572 | $34.4K |
| BlackRock, Inc. | 61,608 | $30.9K |
| State Street Corp | 51,573 | $25.9K |
| HRT Financial LP | 33,798 | $16.0K |
| XTX Topco Ltd | 21,168 | $10.6K |
| LPL Financial LLC | 20,704 | $10.4K |
| Two Sigma Securities, LLC | 16,792 | $8.42K |
| Barclays PLC | 6,012 | $3.02K |
| Wells Fargo & Company | 4,000 | $2.01K |
| Bank of America Corp | 1,593 | $798 |
| TD Waterhouse Canada Inc. | 1,120 | $550 |
| Advisor Group Holdings, Inc. | 647 | $323 |
| Riggs Asset Managment Co. Inc. | 400 | $201 |
| Steward Partners Investment Advisory, LLC | 32 | $16 |
| JPMorgan Chase & Co | 22 | $11 |
| Tucker Asset Management LLC | 2 | $1 |
| Avion Wealth | 1,500 | $0 |
Not filed for Q4 2024 yet (1)
Institutions that held Biora Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Athyrium Capital Management, LP | 10,929,762 | $5.48M |